statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush Initiates a Buy Rating on Argenx Se (ARGX)

Argenx Se (ARGX Research Report) received a Buy rating and a $560.00 price target from Wedbush analyst David Nierengarten today. The company's sh...

JMP Securities Sticks to Their Buy Rating for Argenx Se (ARGX)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Argenx Se (ARGX Research Report), with a price target of...

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that Chinas National Medical Products Administration (NMPA) approved the Biologics License Application...

UBS Keeps Their Hold Rating on Argenx Se (ARGX)

UBS analyst Xian Deng maintained a Hold rating on Argenx Se (ARGX Research Report) today and set a price target of $435.00. The company's shares...

argenx SE (NASDAQ:ARGX) Position Boosted by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. increased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 30.4% in the fourth quarter, according to its most recent 13F filing with the...

Here's Why argenx SE (ARGX) Pulled Back 23% in Q4

TimesSquare Capital Management, an equity investment management company, released its U.S. Mid Cap Growth Strategy fourth-quarter investor letter. A copy of the same can be downloaded here. In the...

Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ARGX stock, giving a Buy rating on March 27. Thomas Smith has given hi...

Values First Advisors Inc. Sells 998 Shares of argenx SE (NASDAQ:ARGX)

Values First Advisors Inc. decreased its holdings in argenx SE (NASDAQ:ARGX  Free Report) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET...

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

March 26, 2024 Amsterdam, the Netherlands argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Volume	770,065.00
52-Wk High	$532.60
52-Wk Low	$327.73

ARGX Argenx

About

Feed

News

Sentiment

Earnings

Fundamentals